Loading...
OTCM
GTHP
Market cap20mUSD
Dec 05, Last price  
0.25USD
1D
0.00%
1Q
-10.71%
Jan 2017
-53.58%
Name

Guided Therapeutics Inc

Chart & Performance

D1W1MN
OTCM:GTHP chart
P/E
—
P/S
2,985.68
EPS
—
Div Yield, %
—
Shrs. gr., 5y
76.98%
Rev. gr., 5y
-27.93%
Revenues
7k
-92.86%
983,000977,0001,037,0001,317,0001,550,0003,364,0003,597,0003,410,0001,179,000823,000606,000605,000244,00057,00036,000102,00081,00013,00098,0007,000
Net income
-2m
L-30.73%
-2,070,000-4,948,0003,016,000-4,810,000-6,212,000-2,846,000-6,644,000-4,353,000-7,215,000-9,883,000-6,902,000-3,970,000-10,696,0001,016,000-3,381,000-1,335,000-3,727,000-4,972,000-3,489,000-2,417,000
CFO
-1m
L-35.91%
-3,507,000-3,575,000-3,944,000-1,909,000-1,420,000-347,000-2,734,000-3,666,000-5,556,000-6,283,000-4,043,000-1,802,000-1,144,000-1,365,000-806,000-1,875,000-1,592,000-1,478,000-1,746,000-1,119,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
URL
https://www.guidedinc.com/
IPO date
Jul 01, 1997
Employees
6
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT